Following a full submission
AWMSG advice |
|||
| Status: Recommended with restrictions | |||
Hydroxycarbamide (Xromi®) is recommended as an option for restricted use within NHS Wales. Hydroxycarbamide (Xromi®) is licensed for the prevention of vaso-occlusive complications of sickle cell disease in patients over two years of age. Hydroxycarbamide (Xromi®) is restricted for use for patients over two years of age who are unable to swallow capsules. Hydroxycarbamide (Xromi®) is not recommended for use within NHS Wales outside of this subpopulation. |
|||
|
|||
Medicine details |
|||
| Medicine name | hydroxycarbamide (Xromi®) | ||
| Formulation | 100 mg/ml oral solution | ||
| Reference number | 4264 | ||
| Indication | Prevention of vaso-occlusive complications of sickle cell disease in patients over 2 years of age |
||
| Company | Nova Laboratories Ltd | ||
| BNF chapter | Cardiovascular system | ||
| Submission type | Full | ||
| Status | Recommended with restrictions | ||
| Advice number | 0620 | ||
| NMG meeting date | 25/06/2020 | ||
| AWMSG meeting date | 15/07/2020 | ||
| Date of issue | 04/08/2020 | ||
| Commercial arrangement | None | ||